IP Library Granted Patent US 7,119,171
Granted Patent B2
US 7,119,171 · App. 10/165,155 · Granted Oct 10, 2006

Binding polypeptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,119,171
App. No.
10/165,155
Granted
Oct 10, 2006
Kind
B2
Abstract

The present invention provides modified fibronectin type III (Fn3) molecules, nucleic acid molecules encoding the modified Fn3 molecules, and related vectors and host cells.

Claims (11)

1. A fibronectin type III (Fn3) monobody polypeptide comprising at least two Fn3 β-strand domain sequences with a ioop region linked between each Fn3 β-strand domain sequence, wherein at least one monobody loop region sequence varies as compared to the wild-type (SEQ ID NO:110, FIG. 2 ) loop region sequence by deletion of two to twelve amino acids in the loop region sequence, insertion of at least two to 25 amino acids, or replacement of at least two amino acids in the loop region sequence, and wherein the monobody polypeptide is capable of binding to a target molecule with a dissociation constant of less than 10 −6 moles/liter.

2. The monobody of claim 1 , wherein at least one loop region binds to the target molecule.

3. The monobody of claim 1 , wherein a loop region comprises amino acid residues:

i) from 15 to 16 inclusive in an AB loop;

ii) from 22 to 30 inclusive in a BC loop;

iii) from 39 to 45 inclusive in a CD loop;

iv) from 51 to 55 inclusive in a DE loop;

v) from 60 to 66 inclusive in an EF loop; or

vi) from 76 to 87 inclusive in an FG loop.

4. The monobody of claim 1 , wherein the monobody loop region sequence varies from a corresponding wild-type Fn3 loop region sequence by the replacement of at least two amino acids in the loop region or the deletion of two to twelve amino acids in the loop region.

5. The monobody of claim 1 , wherein the monobody loop region sequence varies from a corresponding wild-type Fn3 loop region sequence by the insertion of from two to 25 amino acids.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 10, 2019
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 050681/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2011
From: NOVARTIS INTERNATIONAL PHARMACEUTICALS LTD.
To: NOVARTIS AG
Reel/Frame 027394/0397 →